Effective July 29, 2020, oseltamivir phosphate (Tamiflu®) has been added to the ADAP formulary. According to guidelines from the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices, people living with HIV are considered to be at high risk for serious influenza-related complications. Additionally, the CDC recommends prompt treatment of influenza with antivirals, such as oseltamivir phosphate, to prevent serious influenza complications. For these reasons ADAP has added both the brand and generic forms of oseltamivir phosphate to the ADAP formulary.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary
has been updated to reflect the addition of oseltamivir phosphate. Access to the updated formulary is available at the following URL: https://cdph.magellanrx.com/member/documents
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health